Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
fhit Alterations in endometrial carcinoma and hyperplasia.
Ozaki K, Enomoto T, Yoshino K, Hongbo S, Nakamura T, Fujita M, Kuragaki C, Sakata M, Kurachi H, Murata Y. Ozaki K, et al. Among authors: kuragaki c. Int J Cancer. 2000 Feb 1;85(3):306-12. doi: 10.1002/(sici)1097-0215(20000201)85:3<306::aid-ijc2>3.0.co;2-r. Int J Cancer. 2000. PMID: 10652418
Chemotherapy for endometrial carcinoma (GOGO-EM1 study): TEC (paclitaxel, epirubicin, and carboplatin) is an effective remission-induction and adjuvant therapy.
Egawa-Takata T, Ueda Y, Kuragaki C, Miyake T, Miyatake T, Fujita M, Yoshino K, Nakashima R, Okazawa M, Tsutsui T, Morishige K, Kimura T, Yamasaki M, Nishizaki T, Nagamatsu M, Ito K, Asada M, Ogita K, Wakimoto A, Yamamoto T, Nishio Y, Enomoto T. Egawa-Takata T, et al. Among authors: kuragaki c. Cancer Chemother Pharmacol. 2011 Dec;68(6):1603-10. doi: 10.1007/s00280-011-1638-4. Epub 2011 May 17. Cancer Chemother Pharmacol. 2011. PMID: 21584840 Clinical Trial.
Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin.
Ueno Y, Enomoto T, Otsuki Y, Sugita N, Nakashima R, Yoshino K, Kuragaki C, Ueda Y, Aki T, Ikegami H, Yamazaki M, Ito K, Nagamatsu M, Nishizaki T, Asada M, Kameda T, Wakimoto A, Mizutani T, Yamada T, Murata Y. Ueno Y, et al. Among authors: kuragaki c. Cancer Lett. 2006 Sep 28;241(2):289-300. doi: 10.1016/j.canlet.2005.10.035. Epub 2006 Feb 3. Cancer Lett. 2006. PMID: 16459017
Concurrent weekly nedaplatin, external beam radiotherapy and high-dose-rate brachytherapy in patients with FIGO stage IIIb cervical cancer: a comparison with a cohort treated by radiotherapy alone.
Mabuchi S, Ugaki H, Isohashi F, Yoshioka Y, Temma K, Yada-Hashimoto N, Takeda T, Yamamoto T, Yoshino K, Nakajima R, Kuragaki C, Morishige K, Enomoto T, Inoue T, Kimura T. Mabuchi S, et al. Among authors: kuragaki c. Gynecol Obstet Invest. 2010;69(4):224-232. doi: 10.1159/000273207. Epub 2010 Jan 7. Gynecol Obstet Invest. 2010. PMID: 20068328
Hemoperitoneum as the first manifestation of acute leukemia.
Nishimoto F, Okuno K, Kuragaki C, Miyanishi K, Boku K, Yamamoto T. Nishimoto F, et al. Among authors: kuragaki c. Gynecol Obstet Invest. 2008;66(1):12-3. doi: 10.1159/000114249. Epub 2008 Jan 30. Gynecol Obstet Invest. 2008. PMID: 18230909
[Two cases of myotonic dystrophy diagnosed by DNA analysis].
Shukuta T, Hojo K, Kuragaki C, Fujita T, Kidoguchi K, Maeda K, Suehara N. Shukuta T, et al. Among authors: kuragaki c. Nihon Sanka Fujinka Gakkai Zasshi. 1995 Apr;47(4):433-6. Nihon Sanka Fujinka Gakkai Zasshi. 1995. PMID: 7730701 Japanese. No abstract available.
11 results